KTTA (Pasithea Therapeutics Corp.) Stock Market Reviews

crown

search

Read and share opinions on KTTA (Pasithea Therapeutics Corp.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock mar

KTTA

Pasithea Therapeutics Corp.

clarify Biotechnology

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients
Nov 4, 2025
Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients
Sep 16, 2025
Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
Sep 8, 2025
Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
Aug 29, 2025
Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Aug 28, 2025
Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
Jul 31, 2025
Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board
Jun 11, 2025
Pasithea Therapeutics Announces Closing of $5 Million Public Offering
May 7, 2025
Pasithea Therapeutics Announces Pricing of $5 Million Public Offering
May 6, 2025
Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004
May 6, 2025
Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients
Apr 29, 2025
Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting
Apr 24, 2025
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
Apr 10, 2025
Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference
Mar 24, 2025

Reviews